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Background: Epigenetic silencing of tumor suppressor genes plays important role in gliomagenesis. Recently,
GATA4 and DcR1 were suggested to be a tumor suppressor genes involved in tumorigenesis in various types of
human cancers. However, up to now the methylation frequency of GATA4 and DcR1 genes has not been
determined in glioblastoma. In this study, we investigated methylation of GATA4 and DcR1 promoters and their
association with patient prognosis in glioblastoma.
Methods: Methylation status of GATA4 and DcR1 promoters was investigated by methylation specific PCR in 99
glioblastoma patients. Statistical analyses were conducted to investigate the association between clinical variables
and overall survival time.
Results: GATA4 and DcR1 were aberrantly methylated in 23.2% and 27.6% of glioblastoma tumors, but not in
normal brain. GATA4 promoter hypermethylation showed significant association with patients age (p = 0.027).
Relationship between genes promoter methylation and glioblastoma patient survival was not determined.
Conclusions: The present work demonstrated that GATA4 and DcR1 promoter hypermethylation is tumor specific
event in glioblastoma but they promoter methylation cannot be considered as a prognostic marker of glioblastoma
survival.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1381170351801852
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Glioblastoma multiforme (GBM) is the most common
and most aggressive malignant primary brain tumor in
humans. Despite multimodality treatment, prognosis is
poor, with a median survival time of approximately
14 months. Therefore looking for new markers which
would help better diagnose and predict the course of
glioblastoma is important. Understanding apoptosis in
disease conditions is very important as it not only gives
insights into the pathogenesis of a disease but may also
leave clues on how the disease can be treated [1]. Apop-
tosis activation can be triggered either by engagement of
cell surface “death receptors” or by cellular stress [2]. The
proteins of Bcl-2 family are key regulators of the stress-
induced apoptotic pathway [2]. Although, much is known
about the pathways and mechanisms of apoptosis, but the* Correspondence: p.grigaite@gmail.com
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reproduction in any medium, provided the orsignificance of some genes is not fully clear. Our interests
have focused on two genes GATA4 and DcR1, which are
related to apoptosis. Both of these genes are located on
chromosome 8p region. Despite 8p being a relatively small
chromosome arm, it is one of the most frequently altered
genomic regions in human cancer, and is also rich in
candidate oncogenes and tumor suppressor genes asso-
ciated with the development of certain types of cancers
[3]. Deletions in this region are observed in glioblastoma
[4]. As an alternative to deletion GATA4 and DcR1 pro-
moter methylation may be associated with clinical data of
glioblastoma patients. GATA4 is a member of the GATA
family of zinc finger transcription factor, which regulates
gene transcription by binding to GATA elements. GATA4
serves as a survival factor in cancer cells by regulating the
expression of anti-apoptotic Bcl-2 and Bcl-x L [5]. Al-
though GATA4 was expressed in normal brain, loss of
GATA4 expression was observed in 57.6% (94/163) GBM
operative samples and it was a negative survival prognos-
tic marker [6]. According to these data was formedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.diagnosticpathology.org/content/8/1/7hypothesis that promoter methylation of GATA4 gene
could be survival prognostic marker.
The protein encoded by DcR1 gene is a member of the
TNF-receptor superfamily. This receptor is not capable
of inducing apoptosis, and is thought to function as an
antagonistic receptor that protects cells from TRAIL-
induced apoptosis. The expression of this gene was
detected in many normal tissues but not in most cancer
cell lines, which may explain the specific sensitivity of
cancer cells to the apoptosis-inducing activity of TRAIL
[7]. Methylation of DcR1 gene promoter was determined
in 21% of low grade gliomas [8] suggesting its role in
gliomagenesis.
In this study, we evaluated the methylation status of
GATA4 and DcR1 promoters in glioblastoma tumor tis-
sue to support the hypothesis that they are inactivated in
glioblastomas by promoter hypermethylation and plays a
role as tumor suppressor genes in gliomagenesis.Methods
Glioblastoma tumor tissue and normal brain
In total, 99 glioblastoma tumor samples from initial sur-
gery were collected in Neurosurgery clinics of Hospital
of Lithuanian University of Health Sciences (Kaunas,
Lithuania) through 2003 to 2009 yr. Written patient
consent under the approval of ethics committee of
Lithuanian University of Health Sciences was obtained
for every patient. Data base closure was in November
2010. Glioblastoma Multiforme WHO grade IV (Original
SNOMED ID M-94403) diagnoses were established by
experienced pathologists according to the World Health
Organization (WHO) classification. We included Human
brain DNA (Zymo Research, USA) as normal brain con-
trol. Glioblastoma samples were stored in liquid nitrogen
before DNA extraction. The following clinical data were
determined for each patient: age at the time of the ope-
ration, gender, tumor multifocality, time of the last follow-
up and patient status. Survival time was collected for all
cases and overall survival calculated from the date of the
operation to death, or last contact to the live patients.DNA isolation and bisulfate modification
Tumor DNA was extracted from 25-40 mg of frozen tis-
sue using ZR Genomic DNATM Tissue MiniPrep (ZymoTable 1 Primers for MSP





M – methylated, U – unmethylated, Tm – melting temperature.Research, USA) according to manufactures protocol.
The methylation status of GATA4 and DcR1 promoters
was determined by bisulfite treatment of DNA. 400 ng
DNA was used for bisulfite modification. DNA modifi-
cation was performed using EZ DNA Methylation Kit
(Zymo Research, USA), and all procedures were done
according to manufactures protocol. Bisulfite treated
DNA was eluted in 40 μl distilled water, and stored
in −80°C until MS-PCR.
Methylation-specific PCR
The methylation status of the GATA4 and DcR1 promo-
ters region was determined by methylation-specific PCR.
Primers distinguishing unmethylated (U) and methylated
(M) alleles were taken from articles [9,10] are shown as
follows in Table 1.
Each PCR reaction contained 20 ng of sodium
bisulphite-modified DNA. MSP reaction was performed
in 20 μl of total volume, using 10 μl MaximaW Hot Start
PCR Master Mix (Thermo fisher Scientific, USA) with
Hot start Taq DNA polymerase and 10pmol of each pri-
mer (Metabion International AG, Germany). Cycling
conditions were initial denaturation at 95°C for 5 min,
38 cycles of 94°C for 30 s, 60/62°C for 1 min and 72°C
for 1 min and final step at 72°C for 5 min. For each set
of methylation specific PCR reactions human blood
lymphocyte DNA treated with bisulfite served as a
unmethylated DNA control and as positive methylation
control was used ‘Bisulfite Converted Universal Methy-
lated Human DNA Standard’ (Zymo Research, USA). A
water blank control was also included. PCR products
were separated on 2% agarose gels with ethidium bro-
mide and visualized under UV illumination. PCR ana-
lyses were repeated.
Statistical analysis
SPSS Statistics 19 (SPSS Inc., Chicago, IL) software
package was used for statistical analysis. The quantitative
data presented as median and to show the reliability of
the estimate, the confidence interval (CI) with 95% con-
fidence level was presented. Association between gene
methylation data and clinical features of glioblastoma
patients were evaluated by using Fisher exact test. To es-
timate survival functions Kaplan-Meier method was
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sidered significant.
Results
Characteristics of glioblastoma patients
The median age at diagnosis was 61.0 yr. (CI: 57.3-64.7).
The male to female ratio was: 1:1.3. The median age of
males (n = 42) was 58.0 yr. (CI: 52.1-63.9) and females
(n = 57) 61.0 yr. (CI: 56.9-65.1). Median survival time of
glioblastoma patients (n = 99) was 8.9 months (CI: 6.9-
10.8). Most of glioblastoma patients (64%) survived less
than 12 months after operation.
GATA4 and DcR1 promoters are methylated in
glioblastoma
The methylation status of the GATA4 and DcR1 promoter
in glioblastoma samples was detected by methylation-
specific PCR assay. We evaluated methylation status ofFigure 1 Analysis of GATA4 and DcR1 in glioblastoma; Analysis of GA
glioblastoma by the methylation-specific PCR assay. Molecular weight
unmethylated DNA control, W- water control, GB1-GB14 glioblastoma tumo
products in those lanes marked “U” indicates the presence of unmethylated
Kaplan-Meier cumulative survival (months) in glioblastoma patients accordi
(D) DcR1 (log-rank test, p = 0.546).the GATA4 promoter in 95 glioblastoma tumors. Pro-
moter hypermethylation was detected in 23.2% (22/95) of
the glioblastoma but not in normal brain. Representative
samples are shown in Figure 1. The same studies were
performed with DcR1 gene promoter in 98 glioblastoma
samples. DcR1 gene promoter hypermethylation was
detected in 27.6% (27/98) of the glioblastoma tumors but
not in normal brain.
The detection of bands with both primer sets were
found in some but not all of the glioblastoma samples
likely because of the existence of non-malignant cells in
a fraction of the samples or that only one allele of the
gene is methylated.
Among 22 GATA4-methylated cases, five patients
(23%) were younger than 60 years and 17 individuals
(77%) were older than 60 years. There is significant dif-
ference in gene methylation ratio between age groups
(Fisher’s Exact test 2-sided, p = 0.027; Table 2) and thisTA4 (A) and DcR1 (B) CpG island promoter methylation status in
markers are shown in the left, mDNA- methylated DNA control, uDNA-
r samples, NB normal brain sample. The presence of visible PCR
allele genes and “M” indicates the presence of methylated genes.
ng to methylation status of (C) GATA4 (log-rank test, p = 0.15) and





significanceMethylated Unmethylated Methylated Unmethylated
Overall 22 73 27 71
Age (years) 0.027 1.000
<60 years 5 37 12 32
≥60 years 17 36 15 39
Gender 0.473 0.263
Male 11 30 9 33
Female 11 43 18 38
Multifocal 1.000 0.185
Yes 2 5 0 7
No 20 68 27 64
Survival (months) 0.227 1.000
<24 20 57 22 57
≥24 2 16 5 14
DcR1 0.185 -
Methylated 9 18 - -
Unmethylated 13 53
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while, the interface between the DcR1 promoter methy-
lation status and age is unspecified. No dependences
were found between GATA4 and DcR1 promoter methy-
lation and two-year survival time. These genes promoter
methylation was not significantly associated with gender
or tumor multifocality too (Table 2). In no one of multi-
focal glioblastomas DcR1 promoter methylation was
observed. Maybe the study of a large number of samples
could show that DcR1 is an important marker. We ana-
lyzed GATA4 and DcR1 promoter methylation for prog-
nostic value of overall survival (OS) using Kaplan-Meier
Curves (p values were generated using the log-rank test)
(Figure 1C, D). Analysis showed no association between
GATA4 and DcR1 gene promoter methylation and sur-
vival in glioblastomas.
Discussion
Understanding of the molecular alterations that occur
during tumorigenesis, and identification of novel mar-
kers for cancer diagnosis and novel targets for treatment,
may be important for the improvements in tumor diag-
nosis, treatment and prevention [11]. The most common
molecular alterations, that characterize glioblastomas
and could be used in current clinical practice and thera-
peutic decision making, are proliferation markers (Ki-
67/MIB-1 and phospho-histone-H3 (PHH3)), mutations
involving isocitrate dehydrogenase (IDH1 and IDH2)
and TP53, also 1p/19q deletion, mutations of Epidermal
growth factor receptor (EGFR), O-6-methylguanine-DNAmethyltransferase (MGMT) promoter methylation status
and glioma-CpG island methylator phenotype [12-14].
Despite extensive efforts at defining biological markers,
therapeutic progress for glioblastoma is slow. A further
understanding of glioma biology, in concert with well-
designed clinical trials, is necessary to identify more puta-
tive molecular biomarkers and unravel the mysteries in
the pathogenic mechanisms that trigger this menacing
disease [12]. The identification of methylated genes in
cancer may provide an insight in the molecular mechan-
isms of tumor development and might reveal new tools to
define markers of prognostic significance [15]. In order to
identify molecular markers relevant to glioblastoma devel-
opment, diagnosis and prognosis promoter methylation
analysis of 2 genes, DcR1 and GATA4, was performed.
Loss of GATA4 expression due to promoter hyper-
methylation has been reported in primary colorectal,
gastric, esophageal, lung and ovarian cancer [10,16]. To
analyze the potential of GATA4 as methylation marker
in glioblastoma, we analyzed large series of glioblastoma
tumor samples and one normal brain tissue. Were
showed that methylation of GATA4 (23.2%) occurs not
at so high frequencies in glioblastoma as in colorectal
cancer (70%) [10] or sporadic gastric carcinomas (53.8%)
[10]. Loss of GATA4 was observed in about 57.7% GBM
operative samples [6]. In our study GATA4 methylation
was detected only in 23.2% of cases, and this may suggest
that the GATA4 expression is regulated by different
mechanisms or mutation. This could explain the lack of
links between GATA4 promoter methylation and survival
Vaitkienė et al. Diagnostic Pathology 2013, 8:7 Page 5 of 5
http://www.diagnosticpathology.org/content/8/1/7(p = 0.15) in our study contrary to results obtained in
Agnihotri et al. (2011) expression studies [6].
A tumor necrosis factor receptor or death receptor fam-
ily members were found frequently methylated in glio-
blastoma: TNFRSF10D promoter methylated in 100% [8],
and TNFRSF10A in 68% [11] of glioblastomas. Methyla-
tion of DcR1 gene promoter was determined in 21% of
low grade gliomas (LGGs; World Health Organization
[WHO] grade II) [8]. There is not much data about DcR1
promoter methylation in glioblastoma. Martinez et al.
(2007) in 16 glioblastoma patients did not found methyla-
tion of DcR1 promoter [17]. We have assumed that in
glioblastomas this percentage should be much higher. Our
research has established that methylation of DcR1 was in
27.6% of glioblastoma samples, but not in the normal
brain DNA, which implied that epigenetic silencing of the
DcR1 might be involved in gliomagenesis. This number is
close to 37% in lung cancer cell lines or 30.7% in ovarian
tumors and is very different from 78.0% methylation in
prostate cancer [18-20]. These findings suggest that the
prognostic value of promoter hypermethylation of DcR1
could be tissue-specific. The study of gene methylation
impact on survival found that the methylation is not asso-
ciated with survival (p = 0.54). Although promoter hyper-
methylation of GATA4 and DcR1 genes were found in
glioblastoma, they were not associated with patient sex or
tumor multifocality in our series. Meanwhile, it was found
that GATA4 methylation is related to age (p = 0.027).
Conclusion
In conclusion, the present work demonstrated that
GATA4 and DcR1 promoter hypermethylation is tumor
specific event in glioblastoma but they promoter methy-
lation cannot be considered as a prognostic marker in
glioblastoma.
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